The Bacille Calmette-Gu\'erin (BCG) tuberculosis vaccine has immunity benefits against respiratory infections. Accordingly, it has been hypothesized that it may have a protective effect against COVID-19. 12 randomized controlled trials are currently underway to test this hypothesis, but their results shall not be available before at least five months. Instead, this paper uses a nationwide natural experiment . In April 1975, Sweden discontinued newborns BCG vaccination . The vaccination rate fell from 92\% to 2\% . I compare the numbers of COVID-19 cases and hospitalizations for cohorts born just before and just after that change . I find no statistically significant differences, and I can reject small BCG effects. Thus,receiving the BCG vaccine at birth does not seem to have a protective effect against COVID-19. ] ]\\%DIF > confidence that universal BCG vaccination reduces the number of cases by more than 20\% and the number of hospitalizations by more than 24\%. While the effect of a recent vaccination must be evaluated, we provide strong evidence that receiving the BCG vaccine at birth does not have a protective effect against COVID-19.
The Bacille Calmette-Gu\'erin (BCG) tuberculosis vaccine has immunity benefits against respiratory infections. Accordingly, it has been hypothesized that it may have a protective effect against COVID-19. Recent research found that countries with universal Bacillus Calmette-Gu\'erin (BCG) childhood vaccination policies tend to be less affected by the COVID-19 pandemic. However, such ecological studies are biased by numerous confounders. Instead, this paper takes advantage of a rare nationwide natural experiment that took place in Sweden in 1975, where discontinuation of newborns BCG vaccination led to a dramatic fall of the BCG coverage rate from 92\% to 2\% , thus allowing us to estimate the BCG's effect without all the biases associated with cross-country comparisons. Numbers of COVID-19 cases and hospitalizations were recorded for birth cohorts born just before and just after that change , representing 1,026,304 and 1,018,544 individuals, respectively. We used regression discontinuity to assess the effect of BCG vaccination on Covid-19 related outcomes. This method used on such a large population allows for a high precision that would be hard to achieve using a classical randomized controlled trial. The odds ratio for Covid-19 cases and Covid-19 related hospitalizations were 0.9997 (CI95: 0.8002-1.1992]) and 1.1931 (CI95: 0.7558-1.6304]), respectively. We can thus reject with 95\\%DIF > confidence that universal BCG vaccination reduces the number of cases by more than 20\% and the number of hospitalizations by more than 24\%. While the effect of a recent vaccination must be evaluated, we provide strong evidence that receiving the BCG vaccine at birth does not have a protective effect against COVID-19.
R
12 randomized controlled trials are currently underway to test this hypothesis, but their results shall not be available before at least five months.
Recent research found that countries with universal Bacillus Calmette-Gu\'erin (BCG) childhood vaccination policies tend to be less affected by the COVID-19 pandemic. However, such ecological studies are biased by numerous confounders.
R
uses a
takes advantage of a rare
R
. In April
that took place in Sweden in
R
Sweden discontinued
where discontinuation of
R
. The vaccination rate fell
led to a dramatic fall of the BCG coverage rate
R
. I compare the numbers
, thus allowing us to estimate the BCG's effect without all the biases associated with cross-country comparisons. Numbers
R
for
were recorded for birth
R
. I find no statistically significant differences, and I can reject small BCG effects. Thus,receiving the BCG vaccine at birth does not seem to have a protective effect against COVID-19.
, representing 1,026,304 and 1,018,544 individuals, respectively. We used regression discontinuity to assess the effect of BCG vaccination on Covid-19 related outcomes. This method used on such a large population allows for a high precision that would be hard to achieve using a classical randomized controlled trial. The odds ratio for Covid-19 cases and Covid-19 related hospitalizations were 0.9997 (CI95:
A
0.8002-1.1992
A
) and 1.1931 (CI95:
A
0.7558-1.6304
A
), respectively. We can thus reject with 95